The cytokine microenvironment of human colon carcinoma: Lymphocyte expression of tumor necrosis factor-α and interleukin-4 predicts improved survival

Cancer

Volumn 78, Issue 6, 1996, Pages 1168-1178

  Barth Jr , Richard J ^a   Camp, Benjmain J ^a   Martuscello, Teresa A ^a   Dain, Bradley J ^a   Memoli, Vincent A ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

colon carcinoma; granulocyte macrophage colony stimulating factor; interferon ; interleukin 10; interleukin 2; interleukin 4; transforming growth factor ; Tumor infiltrating lymphocytes; tumor necrosis factor

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PREDICTION; PRIORITY JOURNAL; SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE;

CARCINOMA; COLONIC NEOPLASMS; CYTOKINES; EPITHELIUM; FOLLOW-UP STUDIES; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOTOXIN-ALPHA; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9544237126     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960915)78:6<1168::AID-CNCR2>3.0.CO;2-6     Document Type: Article

References (46)

1. DiGiorgio A, Botti C, Tocchi A, Mingazzini P, Flammia M. The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients. Int Surg 1992;77:256-60.
2. Murray AG, Hreno A, Dutton J, Hampson LG. Prognosis in colon cancer. A pathologic reassessment. Arch Surg 1975;110:908-13.
3. Carlon CA, Fabris G, Arslan-Pagnini C. Prognostic correlation of operable carcinoma of the rectum. Dis Colon Rectum 1985;24:47-50.
4. Horn S, Rosenberg S, Topalian S. Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion. Cancer Immunol Immunother 1993;36:1-8.
5. Yoo YK, Heo DS, Hata K, Van Thiel DH, Whiteside T. Tumor-infiltrating lymphocytes from human colon carcinomas-Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology 1990;98:259-68.
6. Barth RJ, Mulé J, Spiess P, Rosenberg S. Interferon γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991;173:647-58.
7. Camp B, Dyhrman S, Memoli V, Mott L, Barth RJ. In situ cytokine production by breast cancer tumor infiltrating lymphocytes. Ann Surg Oncol 1996;3:176-84.
8. Gastl G, Abrams J, Nanus D, Oosterkamp R, Silver J, Liu F, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993;55:96-101.
9. Avery A, Paraskeva C, Hall P, Flanders KC, Sporn M, Moorghen M. TGF-β expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer 1993; 68:137-9.
10. Sato Y, Mukai K, Watanabe S, Goto M, Shimosato Y. The AMeX method: a simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 1986;125:431-5.
11. Conover WJ. Practical nonparametric statistics. 2nd edition. New York: John Wiley and Sons, 1980.
12. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
13. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons, 1980.
14. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. 4th edition. Philadelphia: JB Lippincott, 1992.
15. deWaal Malefyt R, Yssel H, deVries JE. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. J Immunol 1993;150:4754-65.
16. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 1994;153:811-6.
17. deWaal Malefyt R, Abrams JS, Bennet BJ, Figdor CG, deVries JE. IL-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
18. Barth RJ, Coppola M, Green W. The in vivo effects of locally secreted IL-10 on the murine anti-tumor immune response. Ann Surg Oncol 1996;3:381-6.
19. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with Interleukin (IL)-2, IL-6, IL-7, IL-10, tumor necrosis factor a, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res 1994;54:6022-6.
20. Suzuki T, Tahara H, Narula S, Moore K, Robbins P, Lotze M. Viral IL-10, the human herpes virus 4 cellular homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 1995;182:477-86.
21. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Melchor A, Rik D, et al. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986;163:1037-50.
22. Chen Y, Kuchroo V, Inobe J, Hafler D, Weiner H. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-40.
23. 1. Exp Cell Res 1989;181:442-53.
24. 1 with tumor progression. Cell Growth Differ 1994;5:267-75.
25. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF β receptors in colon cancer cells with microsatellite instability. Science 1995;268:1336-9.
26. 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995;4:549-54.
27. Naylor MS, Stamp GWH, Balkwill F. Investigation of cytokine gene expression in human colorectal cancer. Cancer Res 1990;50:4436-40.
28. Pace JL, Russell SW, Torres BA, Johnson HM, Gray PW. Recombinant mouse IFN y induces the priming step in macro-phage activation for tumor cell killing. J Immunol 1983; 130:2011-6.
29. Cavallo F, DiPierro F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, et al. Protective and curative potential of vaccination with interleukin 2 gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res 1993;53:5067-70.
30. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 1994;179:1109-18.
31. Larsen C, Ritchie S, Hendrix R, Linsley P, Hathcock K, Hodes R, et al. Regulation of immunostimulatory functions and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 1994;152:5208-14.
32. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90:3539-43.
33. Lahm H, Schnyder B, Wyniger J, Borbenyt Z, Yilmaz A, Car B, et al. Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors. Int J Cancer 1994;59:440-7.
34. Toi M, Bicknell R, Harris A. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992;52:275-9.
35. Topp M, Papadimitriou C, Eitelbach F, Koenigsmann M, Oelmann E, Koehler B, et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res 1995;55:2173-6.
36. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994;153:5659-65.
37. Beissert S, Bergholz M, Waase I, Lepsien G, Schauer A, Pfizenmaier K, et al. Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc Natl Acad Sci USA 1989; 86:5064-8.
38. Numata A, Minagawa T, Asano M, Nakane A, Katoh H, Tanabe T. Functional evaluation of tumor-infiltrating mononuclear cells. Cancer 1991;68:1937-43.
39. Sato N, Goto T, Harnaka K, Satomi N, Nariuchi H, Mano-Hirano Y, et al. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition and cytotoxicity. J Natl Cancer Inst 1986;76:1113-21.
40. Asher A, Mulé J, Reichert C, Shiloni E, Rosenberg S. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-74.
41. Talmadge J, Phillips H, Schneider M, Rowe T, Pennington R, Bowersox O, et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988;48:544-50.
42. Trentin L, Zambello R, Bulian P, Cerutti A, Enthammer C, Cassatella M, et al. Tumor-infiltrating lymphocytes bear the 75 kDa tumor necrosis factor receptor. Br J Cancer 1995; 71:240-5.
43. Kemeny N, Childs B, Larchian W, Rosado K, Kelsen D. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 1990; 66:659-63.
44. Asher AL, Mulé JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-α. J Immunol 1991;146:3227-34.
45. Ijzermans J, Scheringa M, van der Schelling G, Geerling R, Marquet R, Jeekel J. Injection of recombinant tumor necrosis factor directly into liver metastases: an experimental and clinical approach. Clin Exp Metastasis 1992;10:91-7.
46. Hwu P, Yanelli J, Kriegler M, Anderson WP, Perez C, Chiang Y, et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-α cDNA for gene therapy of cancer in humans. J Immunol 1993;150:4104-15.